Drug Profile
FT 500
Alternative Names: FT-500; FT500iLatest Information Update: 07 Feb 2023
Price :
$50
*
At a glance
- Originator Fate Therapeutics; University of Minnesota
- Developer Fate Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Nov 2022 Fate Therapeutics completed phase-I trials in Solid tumours (Combination therapy,Monotherapy, Late-stage disease) in USA (Parenteral) (NCT03841110)
- 31 Dec 2021 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (Parenteral) prior to December 2021 (Fate Therapeutics pipeline, March 2022)
- 31 Dec 2021 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in USA (Parenteral) prior to December 2021 (Fate Therapeutics pipeline, March 2022)